Form 4: BioCryst Pharmaceuticals Director Acquires Shares in Lieu of Cash Retainer

Director Vincent Milano acquired 653 shares of BioCryst Pharmaceuticals common stock on February 28, 2025, in lieu of 50% of his quarterly cash board member retainer.

Summary

• On February 28, 2025, Vincent Milano, a director of BioCryst Pharmaceuticals, acquired 653 shares of common stock.
• The shares were issued in lieu of 50% of his quarterly cash Board Member retainer, amounting to $11,250.
• The price per share was $8.61.
• Following the transaction, Milano directly owns 76,737 shares of BioCryst Pharmaceuticals.
• The transaction was reported on March 4, 2025.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects a routine transaction related to director compensation. The director taking shares instead of cash could be seen as a slightly positive signal.

Positives

• Director's decision to take shares instead of cash may signal confidence in the company's future prospects.

Industry Context

Directors often receive compensation in the form of stock to align their interests with those of shareholders. This is a common practice in the pharmaceutical industry.

Related Party Transactions

• The issuance of shares to Vincent Milano, a director, in lieu of cash compensation constitutes a related party transaction.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a small number of shares issued as part of director compensation.

Key Dates